查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585839

支氣管炎治療藥物市場：按適應症、治療方法、藥物類別和最終用戶 - 全球預測 2025-2030

Bronchitis Treatment Market by Indication (Acute Bronchitis, Chronic Bronchitis), Treatment (Drugs, Oxygen Therapy), Class of Drugs, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年支氣管炎治療藥物市值為67.2億美元，預計2024年將達71.6億美元，複合年成長率為6.75%，預計到2030年將達到106.2億美元。

支氣管炎治療藥物市場涵蓋廣泛的醫療干預措施，旨在減輕支氣管炎的症狀並解決支氣管炎的原因，其特徵是肺部支氣管發炎。這些治療範圍從抗生素和支氣管擴張劑等藥物到加濕器和肺部復健等非藥物治療。這種疾病的流行凸顯了對有效支氣管炎治療的需求，而空氣污染、吸菸和病毒感染等因素又加劇了這種疾病。這些治療的應用範圍從急性支氣管炎到慢性支氣管炎，最終用途主要在醫院、診所和居家照護。主要成長動力包括呼吸健康意識的提高、藥物配方的進步以及醫療基礎設施投資的增加。利用基因研究來開發個人化醫療方法，根據患者情況量身訂做更有效的治療方法是有潛在機會的。數位醫療技術提供了另一種成長途徑，透過遠端醫療解決方案改善治療的可近性，特別是在農村地區。

主要市場統計
基準年[2023] 67.2億美元
預測年份 [2024] 71.6億美元
預測年份 [2030] 106.2億美元
複合年成長率（%） 6.75%

儘管有這些機遇，市場仍面臨重大挑戰，包括對長期使用某些藥物的副作用和抗生素抗藥性的擔憂。監管障礙和研發成本也對新治療方法的有效商業化構成障礙。新興市場缺乏意識和獲得醫療保健的機會不足，進一步限制了市場開拓。創新可能會在一些領域蓬勃發展，例如開發聯合治療以提高療效並最大限度地減少副作用，以及在預測分析和患者管理中使用人工智慧來改善治療結果。該市場的特點是競爭激烈，主要企業投資於研發，以實現產品差異化並贏得市場佔有率。透過專注於永續性、加強患者教育以及促進製藥公司、科技公司和公共衛生機構之間的合作，我們可以克服現有的市場限制並實現顯著成長。

市場動態：揭示快速發展的支氣管炎藥物市場的關鍵市場洞察

供應和需求的動態交互作用正在改變支氣管炎藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 慢性阻塞性肺病（COPD）患者增加
    • 政府和私人組織增加醫療保健支出
    • 政府和醫療機構加強意識提升
  • 市場限制因素
    • 替代品的可用性和產品的高成本
  • 市場機會
    • 持續進行研究和開發活動，以改善支氣管炎治療的呼吸治療方法
    • 支氣管炎治療中個人化醫療越來越偏好
  • 市場挑戰
    • 嚴格且耗時的法規環境

波特五力：駕馭支氣管炎藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對支氣管炎治療藥物市場的影響

外部宏觀環境因素在塑造支氣管炎治療藥物市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解支氣管炎治療藥物市場的競爭狀況

支氣管炎治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣支氣管炎治療市場供應商的績效評估

FPNV 定位矩陣是評估支氣管炎治療藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪支氣管炎治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對支氣管炎治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性阻塞性肺病（COPD）患者盛行率上升
      • 政府和私人組織增加醫療保健支出
      • 政府和醫療機構加強提高人們對支氣管炎的認知
    • 抑制因素
      • 替代品的可用性和產品的高成本
    • 機會
      • 持續研發活動以改善支氣管炎治療藥物的呼吸治療
      • 人們對治療支氣管炎的個人化藥物越來越感興趣
    • 任務
      • 耗時且嚴格的法規環境
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 支氣管炎治療藥物市場（依適應症）

  • 急性支氣管炎
  • 慢性支氣管炎

第7章 依治療分類的支氣管炎治療藥物市場

  • 藥品
  • 氧氣療法

第8章 依藥物類型分類的支氣管炎治療藥物市場

  • 發炎藥
  • 抗生素
  • 支氣管擴張劑

第9章支氣管炎治療藥物市場：依最終使用者分類

  • 診所
  • 醫院藥房
  • 零售藥房

第10章 北美和南美支氣管炎治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區支氣管炎治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的支氣管炎治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • American Well Corporation
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Limited
  • Cigna Corporation
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc
  • Lupin Limited
  • Melinta Therapeutics, Inc.
  • Merck and Co. Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Reckitt Benckiser Group PLC
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • TelaCare Health Solutions, LLC
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-A26E0E574296

The Bronchitis Treatment Market was valued at USD 6.72 billion in 2023, expected to reach USD 7.16 billion in 2024, and is projected to grow at a CAGR of 6.75%, to USD 10.62 billion by 2030.

The bronchitis treatment market encompasses a range of medical interventions aimed at relieving symptoms and addressing the causes of bronchitis, a condition characterized by inflammation of the bronchi in the lungs. This market's scope spans pharmaceuticals, including antibiotics and bronchodilators, and non-pharmacological treatments like humidifiers and pulmonary rehabilitation. The necessity for effective bronchitis treatment is underscored by the condition's prevalence, which is exacerbated by factors such as air pollution, smoking, and viral infections. The application of these treatments varies from acute to chronic bronchitis, with primary end-use in hospitals, clinics, and for in-home care. Key growth drivers include increasing awareness about respiratory health, advancements in drug formulations, and rising investments in healthcare infrastructure. There is a potential opportunity in developing personalized medicine approaches, leveraging genetic research to tailor treatments more effectively to patient profiles. Digital health technology offers another growth avenue through telemedicine solutions, improving access to treatment, especially in rural areas.

KEY MARKET STATISTICS
Base Year [2023] USD 6.72 billion
Estimated Year [2024] USD 7.16 billion
Forecast Year [2030] USD 10.62 billion
CAGR (%) 6.75%

Despite these opportunities, the market faces significant challenges, including the side effects associated with long-term use of certain medications and antibiotic resistance concerns. Regulatory hurdles and the cost of research and development also pose barriers to the effective commercialization of new treatments. Market growth is further restrained by a lack of awareness and inadequate healthcare access in developing regions. Innovation can thrive in areas such as the development of combination therapies that enhance efficacy and minimize side effects, or in the utilization of AI for predictive analytics and patient management to improve treatment outcomes. The market is characterized by a competitive nature with key players investing in R&D to differentiate their offerings and capture market share. Maintaining a focus on sustainability, enhancing patient education, and fostering collaborations across pharmaceutical companies, technology firms, and public health organizations can contribute to overcoming existing market limitations and achieving substantial growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bronchitis Treatment Market

The Bronchitis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic obstructive pulmonary disease (COPD) patients
    • Growing healthcare expenditure by governments and private organizations
    • Increasing initiatives by government and healthcare organizations to create awareness about bronchitis
  • Market Restraints
    • Availability of alternatives and high cost of products
  • Market Opportunities
    • Ongoing research and development activities for improving respiratory therapies for bronchitis treatment
    • Increasing preference for personalized medicines for bronchitis treatment
  • Market Challenges
    • Time consuming and stringent regulatory environment

Porter's Five Forces: A Strategic Tool for Navigating the Bronchitis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bronchitis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bronchitis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bronchitis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bronchitis Treatment Market

A detailed market share analysis in the Bronchitis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bronchitis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bronchitis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bronchitis Treatment Market

A strategic analysis of the Bronchitis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchitis Treatment Market, highlighting leading vendors and their innovative profiles. These include American Well Corporation, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Cigna Corporation, Cipla Limited, Dr. Reddy's Laboratories Ltd, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Pharmaceuticals Limited, Johnson & Johnson Services, Inc, Lupin Limited, Melinta Therapeutics, Inc., Merck and Co. Inc., Novartis International AG, Pfizer Inc., Reckitt Benckiser Group PLC, Sanofi S.A, Sun Pharmaceutical Industries Ltd., TelaCare Health Solutions, LLC, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Bronchitis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Acute Bronchitis and Chronic Bronchitis.
  • Based on Treatment, market is studied across Drugs and Oxygen Therapy.
  • Based on Class of Drugs, market is studied across Anti-inflammatory Drugs, Antibiotics, and Bronchodilator.
  • Based on End User, market is studied across Clinics, Hospital Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic obstructive pulmonary disease (COPD) patients
      • 5.1.1.2. Growing healthcare expenditure by governments and private organizations
      • 5.1.1.3. Increasing initiatives by government and healthcare organizations to create awareness about bronchitis
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of alternatives and high cost of products
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development activities for improving respiratory therapies for bronchitis treatment
      • 5.1.3.2. Increasing preference for personalized medicines for bronchitis treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Time consuming and stringent regulatory environment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bronchitis Treatment Market, by Indication

  • 6.1. Introduction
  • 6.2. Acute Bronchitis
  • 6.3. Chronic Bronchitis

7. Bronchitis Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Drugs
  • 7.3. Oxygen Therapy

8. Bronchitis Treatment Market, by Class of Drugs

  • 8.1. Introduction
  • 8.2. Anti-inflammatory Drugs
  • 8.3. Antibiotics
  • 8.4. Bronchodilator

9. Bronchitis Treatment Market, by End User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Hospital Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Bronchitis Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Bronchitis Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Bronchitis Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. American Well Corporation
  • 2. AstraZeneca PLC
  • 3. Boehringer Ingelheim International GmbH
  • 4. Cadila Pharmaceuticals Limited
  • 5. Cigna Corporation
  • 6. Cipla Limited
  • 7. Dr. Reddy's Laboratories Ltd
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. GlaxoSmithKline Pharmaceuticals Limited
  • 10. Johnson & Johnson Services, Inc
  • 11. Lupin Limited
  • 12. Melinta Therapeutics, Inc.
  • 13. Merck and Co. Inc.
  • 14. Novartis International AG
  • 15. Pfizer Inc.
  • 16. Reckitt Benckiser Group PLC
  • 17. Sanofi S.A
  • 18. Sun Pharmaceutical Industries Ltd.
  • 19. TelaCare Health Solutions, LLC
  • 20. Teva Pharmaceutical Industries Ltd.
  • 21. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. BRONCHITIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. BRONCHITIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BRONCHITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BRONCHITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BRONCHITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BRONCHITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRONCHITIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRONCHITIS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY ACUTE BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY BRONCHODILATOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHITIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES BRONCHITIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM BRONCHITIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM BRONCHITIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM BRONCHITIS TREATMENT MARKET SIZE, BY CLASS OF DRUGS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM BRONCHITIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. BRONCHITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. BRONCHITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023